Home › NCT07449039

Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* Prenatal care at UCLA Health
* Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
* Confirmed gestational diabetes diagnosis based on 2-step approach
* Maternal age \>= 18 years

Exclusion Criteria:

* Pre-gestational diabetes (T1DM or T2DM)
* Multifetal gestation
* Intra-amniotic infection by clinical criteria
* Postpartum hemorrhage
* Maternal ICU admission
* Known allergy to medical-grade adhesive
* Presence of skin lesions at anticipated CGM application site
* Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial
* Metformin use
* Steroid use
* Terbutaline use within 4 hours of delivery
* Cystic fibrosis
* MODY (mature onset of diabetes in the young)

About the study

This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes.

Participants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will also be asked to complete two surveys regarding their experience at 1-3 months postpartum and 12-14 months postpartum.

What is being tested

• Continuous Glucose Monistor (device)

Sponsor: University of California, Los Angeles · Participants: 50 · Started: Sep 28, 2025

Contact the study team

• Rujuta Sathe · Phone: 310-794-8893
• Dana Levin-Lopez, MPH · Phone: 310-794-8893

Official record on ClinicalTrials.gov — NCT07449039

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.